Koskinas Konstantinos C, Van Craenenbroeck Emeline M, Antoniades Charalambos, Blüher Matthias, Gorter Thomas M, Hanssen Henner, Marx Nikolaus, McDonagh Theresa A, Mingrone Geltrude, Rosengren Annika, Prescott Eva B
Department of Cardiology, Bern University Hospital-INSELSPITAL, University of Bern, Freiburgstrasse 18, Bern 3010, Switzerland.
Department of Cardiology, Antwerp University Hospital, Drie Eikenstraat 655, Antwerp 2650, Belgium.
Eur J Prev Cardiol. 2025 Feb 18;32(3):184-220. doi: 10.1093/eurjpc/zwae279.
The global prevalence of obesity has more than doubled over the past four decades, currently affecting more than a billion individuals. Beyond its recognition as a high-risk condition that is causally linked to many chronic illnesses, obesity has been declared a disease per se that results in impaired quality of life and reduced life expectancy. Notably, two-thirds of obesity-related excess mortality is attributable to cardiovascular disease. Despite the increasingly appreciated link between obesity and a broad range of cardiovascular disease manifestations including atherosclerotic disease, heart failure, thromboembolic disease, arrhythmias, and sudden cardiac death, obesity has been underrecognized and sub-optimally addressed compared with other modifiable cardiovascular risk factors. In the view of major repercussions of the obesity epidemic on public health, attention has focused on population-based and personalized approaches to prevent excess weight gain and maintain a healthy body weight from early childhood and throughout adult life, as well as on comprehensive weight loss interventions for persons with established obesity. This clinical consensus statement by the European Society of Cardiology discusses current evidence on the epidemiology and aetiology of obesity; the interplay between obesity, cardiovascular risk factors and cardiac conditions; the clinical management of patients with cardiac disease and obesity; and weight loss strategies including lifestyle changes, interventional procedures, and anti-obesity medications with particular focus on their impact on cardiometabolic risk and cardiac outcomes. The document aims to raise awareness on obesity as a major risk factor and provide guidance for implementing evidence-based practices for its prevention and optimal management within the context of primary and secondary cardiovascular disease prevention.
在过去四十年中,全球肥胖患病率增加了一倍多,目前影响着超过十亿人。肥胖不仅被认为是一种与许多慢性疾病有因果关系的高危状况,还被宣布为一种本身会导致生活质量受损和预期寿命缩短的疾病。值得注意的是,与肥胖相关的额外死亡中有三分之二归因于心血管疾病。尽管肥胖与包括动脉粥样硬化疾病、心力衰竭、血栓栓塞性疾病、心律失常和心源性猝死在内的广泛心血管疾病表现之间的联系越来越受到重视,但与其他可改变的心血管危险因素相比,肥胖一直未得到充分认识和处理。鉴于肥胖流行对公众健康的重大影响,人们的注意力集中在基于人群和个性化的方法上,以防止体重过度增加,并从幼儿期到成年期保持健康体重,以及对已确诊肥胖者进行全面的减肥干预。欧洲心脏病学会的这份临床共识声明讨论了肥胖流行病学和病因学的现有证据;肥胖、心血管危险因素和心脏疾病之间的相互作用;心脏病和肥胖患者的临床管理;以及减肥策略,包括生活方式改变、介入程序和抗肥胖药物,特别关注它们对心脏代谢风险和心脏结局的影响。该文件旨在提高人们对肥胖作为主要危险因素的认识,并为在初级和二级心血管疾病预防背景下实施基于证据的肥胖预防和最佳管理实践提供指导。